AZD9150 — Competitive Intelligence Brief

AZD9150 (AZD9150) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: antisense oligonucleotide. Area: Oncology.

phase 2 antisense oligonucleotide MYC Oncology Small molecule

Target snapshot

AZD9150 (AZD9150) — Acerta Pharma BV. AZD9150 is an antisense oligonucleotide that targets the RNA of the MYC oncogene, leading to reduced expression of MYC protein.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AZD9150 TARGET	AZD9150	Acerta Pharma BV	phase 2	antisense oligonucleotide	MYC
Duac® Gel / Differin® Gel	Duac® Gel / Differin® Gel	Stiefel, a GSK Company	marketed	Topical antibiotic/antimicrobial combination (Duac®); Topical retinoid (Differin®)	Bacterial ribosome (clindamycin); Retinoic acid receptor (adapalene); Reactive oxygen species generation (benzoyl peroxide)
HR	HR	Global Alliance for TB Drug Development	marketed	Anti-tuberculosis agent (fixed-dose combination)	Mycobacterial cell wall (isoniazid) and bacterial RNA polymerase (rifampicin)
clindamycin 1% / benzoyl peroxide 5% tube	clindamycin 1% / benzoyl peroxide 5% tube	Sanofi	marketed	Topical antibiotic combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Clindamycin + BPO	Clindamycin + BPO	GlaxoSmithKline	marketed	Topical antibiotic + oxidizing agent combination	Bacterial 50S ribosome (clindamycin); reactive oxygen species generation (benzoyl peroxide)
Lansoprazole/Amoxicillin/Clarithromycin	Lansoprazole/Amoxicillin/Clarithromycin	HK inno.N Corporation	marketed	Proton pump inhibitor + antibiotic combination	H+ ATPase (lansoprazole); bacterial cell wall (amoxicillin); bacterial ribosome (clarithromycin)
mTOR inhibitor (everolimus)	mTOR inhibitor (everolimus)	Hannover Medical School	marketed	mTOR inhibitor	mTOR (mammalian target of rapamycin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (antisense oligonucleotide class)

1. Acerta Pharma BV · 1 drug in this class
2. Avidity Biosciences, Inc. · 1 drug in this class
3. Hoffmann-La Roche · 1 drug in this class
4. Ionis Pharmaceuticals, Inc. · 1 drug in this class
5. Pfizer · 1 drug in this class
6. Supernus Pharmaceuticals, Inc. · 1 drug in this class
7. Sylentis, S.A. · 1 drug in this class